1
|
Role of Vitronectin and Its Receptors in Neuronal Function and Neurodegenerative Diseases. Int J Mol Sci 2022; 23:ijms232012387. [PMID: 36293243 PMCID: PMC9604229 DOI: 10.3390/ijms232012387] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 10/12/2022] [Accepted: 10/14/2022] [Indexed: 11/06/2022] Open
Abstract
Vitronectin (VTN), a multifunctional glycoprotein with various physiological functions, exists in plasma and the extracellular matrix. It is known to be involved in the cell attachment, spreading and migration through binding to the integrin receptor, mainly via the RGD sequence. VTN is also widely used in the maintenance and expansion of pluripotent stem cells, but its effects go beyond that. Recent evidence shows more functions of VTN in the nervous system as it participates in neural differentiation, neuronutrition and neurogenesis, as well as in regulating axon size, supporting and guiding neurite extension. Furthermore, VTN was proved to play a key role in protecting the brain as it can reduce the permeability of the blood-brain barrier by interacting with integrin receptors in vascular endothelial cells. Moreover, evidence suggests that VTN is associated with neurodegenerative diseases, such as Alzheimer's disease, but its function has not been fully understood. This review summarizes the functions of VTN and its receptors in neurons and describes the role of VTN in the blood-brain barrier and neurodegenerative diseases.
Collapse
|
2
|
Vincent L, Bourneau-Martin D, Maurier A, Babin M, Delepine S, Helley D, Grandvuillemin A, Lagarce L, Lillo-Le Louët A, Briet M. Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review. Therapie 2021; 76:687-693. [PMID: 33726948 DOI: 10.1016/j.therap.2021.02.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 01/15/2021] [Accepted: 02/16/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND Abciximab (ABX) is used for acute coronary syndrome and unstable angina. Thrombocytopenia is a frequent adverse effect described as occurring in the first 24hours. The aim of this study was to evaluate, in a context of pharmacovigilance survey, the occurrence of delayed thrombocytopenia following ABX infusion in pharmacovigilance database reports and in the literature. METHODS Individual case safety reports (ICSRs) of delayed thrombocytopenia-between 3 and 30 days - with ABX presented as a single suspect were selected in VigiBase®, the WHO global database of ICSRs. The French cases were then extracted from the French national pharmacovigilance database. In addition, a literature review of published cases was performed using PubMed. RESULTS Among the 84 ICSRs selected from VigiBase®, 43 were also reported in the FPVD. Mean age was 60.1±12.3 years with a majority of male patients (77.4%). The average time to onset (TTO) was 8.9±5.2 days. Thrombocytopenia regressed in 5.1±2.7 days. Haemorrhagic complications were reported in 15% of ICSRs. In the French cases, the median nadir of platelet count was 28×109/L (range 1-110) with a majority of grade 4 thrombocytopenia (39.5%). The literature review identified 42 cases and provided additional information on administered therapies, which include platelet units, corticosteroids, and IV immunoglobulins. GPIIb/IIIa-ABX complex antibodies were described in 26 published cases. CONCLUSION Delayed thrombocytopenia, probably due to immune reaction, is a possible life-threatening adverse effect of ABX with a mean TTO of 9 days, supporting the recommendation of a platelet count monitoring during at least two weeks. This recommendation was added to the abcximab SmPC in 2019.
Collapse
Affiliation(s)
- Louis Vincent
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - Delphine Bourneau-Martin
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France.
| | - Anaïs Maurier
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - Marina Babin
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - Stéphane Delepine
- Cardiology Department, Angers University Hospital, 49933 Angers, France
| | - Dominique Helley
- Department of Biological Haematology, George Pompidou European Hospital, 75015 Paris, France
| | | | - Laurence Lagarce
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France
| | - Agnès Lillo-Le Louët
- Regional Pharmacovigilance Centre, George Pompidou European Hospital, 75015 Paris, France
| | - Marie Briet
- Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, 4, rue Larrey, 49933 Angers, France; University of Angers, 49933 Angers, France; MitoVasc Laboratory, UMR CNRS 6214 Inserm 1083, 49933 Angers, France
| |
Collapse
|